Solid Biosciences (SLDB) Profit After Tax (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Profit After Tax data on file, last reported at -$56.7 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 44.44% year-over-year to -$56.7 million; the trailing twelve-month figure through Mar 2026 stood at -$191.8 million (down 37.3% YoY), and the FY2025 full-year result was -$174.3 million, down 39.8% from the prior year.
• Profit After Tax fell to -$56.7 million in Q1 2026, from -$49.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$15.2 million in Q4 2022 to a low of -$56.7 million in Q1 2026.
• A 5-year average of -$31.6 million and a median of -$25.3 million in 2022 frame the typical range for Profit After Tax.
• Peak annual rise in Profit After Tax reached 19.18% in 2024, while the deepest fall reached 109.47% in 2024.
• Tracing SLDB's Profit After Tax over 5 years: stood at -$15.2 million in 2022, then sank by 34.22% to -$20.3 million in 2023, then plunged by 109.47% to -$42.6 million in 2024, then declined by 16.88% to -$49.8 million in 2025, then dropped by 13.96% to -$56.7 million in 2026.
• Business Quant data shows SLDB's Profit After Tax at -$56.7 million in Q1 2026, -$49.8 million in Q4 2025, and -$45.8 million in Q3 2025.